All News
Filter News
Found 190 articles
-
CytRx Comments on Quarterly Results and Recent Strategic Initiatives
8/12/2021
CytRx Corporation, a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, commented on its results for the second quarter ended June 30, 2021.
-
CytRx Highlights Preliminary Results of Cohort C of QUILT 88, a Phase 2 Pancreatic Cancer Trial That Includes Aldoxorubicin, Expected to be Released in Q1 2022
7/29/2021
CytRx Corporation (OTCQB: CYTR) ("CytRx" or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted that ImmunityBio, Inc. (NASDAQ: IBRX) (“ImmunityBio”) has been granted a patent by the U.S. Patent and Trademark Office for its proprietary NANT Cancer Vaccine (U.S. Patent 11,071,774).
-
CytRx Announces Director Election Results from 2021 Annual Meeting of Stockholders
7/29/2021
CytRx Corporation announced that based on results from its 2021 Annual Meeting of Stockholders, both of the Company’s Class III director candidates – Joel K. Caldwell, CPA and Jennifer K. Simpson, Ph.D. – have been elected to the Board of Directors.
-
CytRx Corporation Announces Closing of $10 Million Offering to Healthcare-Focused Institutional Investor
7/16/2021
CytRx Corporation today announced the closing of its previously announced sale of its securities pursuant to a securities purchase agreement (the “Purchase Agreement”) to a single healthcare-focused institutional investor (the “Investor”) for aggregate gross proceeds of approximately $10 million.
-
CytRx Corporation Enters Into Securities Purchase Agreement for $10 Million With Healthcare-Focused Institutional Investor
7/13/2021
CytRx Corporation, a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor for aggregate gross proceeds of approximately $10 million.
-
CytRx Comments on Orphazyme’s Promising 24-Month Interim Trial Results of Arimoclomol for Niemann-Pick Disease Type C
6/30/2021
CytRx Corporation recently announced 24-month interim results of an open-label extension (OLE) trial of arimoclomol for the treatment of Niemann-Pick disease type C (NPC).
-
Orphazyme said that its OLE trial, which has been running for the past 24 months, showed that arimoclomol could be an effective and safe option in treating Niemann-Pick disease type C.
-
Orphazyme presents 36-month data supporting durable response to arimoclomol during Parseghian Scientific Conference for NPC Research
6/28/2021
Orphazyme A/S, a late-stage biopharmaceutical company, announced 24-month interim results of an open-label extension trial, providing efficacy and safety data for its investigational treatment arimoclomol in Niemann-Pick disease type C for up to 36 months.
-
Orphazyme announces restructuring to focus resources on supporting a path forward for arimoclomol in NPC
6/28/2021
Orphazyme A/S, a late-stage biopharmaceutical company, announced a restructuring intended to enable the company to advance its corporate strategy and the development of arimoclomol for Niemann-Pick disease type C.
-
Major shareholder announcement - June 24, 2021
6/24/2021
Orphazyme A/S hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Aescap Venture Management B.V, that as of June 16, 2021, Aescap Venture Management B.V indirectly holds shares corresponding to less than 5% of the total share capital and voting rights in the Company.
-
The FDA said that arimoclomol, which has been studied and submitted for NPC indication, needs further data to support its use in this rare, progressive genetic disorder.
-
CytRx Notes Orphazyme’s Regulatory Update from the FDA on Arimoclomol for Niemann-Pick Disease Type C
6/18/2021
CytRx Corporation (OTCQB: CYTR) ("CytRx"), today noted that Orphazyme A/S (NASDAQ: ORPH) ("Orphazyme") announced it has received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) following its review of the new drug application for arimoclomol, a heat shock protein amplifier intended for the treatment of Niemann-Pick disease type C (“NPC”
-
Orphazyme provides regulatory update from FDA on arimoclomol for Niemann-Pick disease type C
6/18/2021
Orphazyme A/S announced it has received a Complete Response Letter from the U.S. Food and Drug Administration following its review of the new drug application for arimoclomol, a heat shock protein amplifier intended for the treatment of Niemann-Pick disease type C.
-
The month of June continues to be busy for the U.S. Food and Drug Administration. There are three PDUFA dates on the calendar for this week. Here’s a look.
-
Orphazyme addresses recent trading activity
6/11/2021
Orphazyme A/S, a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases, announced that American Depositary Shares representing its ordinary shares on Nasdaq US have since June 10, 2021 experienced extreme volatility in price and trading volume.
-
CytRx to Present at Upcoming Investor Conferences
6/2/2021
CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that Steven A. Kriegsman, Chairman and Chief Executive Officer of CytRx, is scheduled to present in the following upcoming conferences: LD Micro Invitational XI Conference: June 8-10, 2021
-
Taysha Gene Therapies Joins the Rare Disease Company Coalition
5/19/2021
Joined an alliance of life science companies dedicated to rare disease therapy development to support advocacy for policies that will improve processes for timely and cost-effective delivery of treatments
-
The Rare Disease Company Coalition’s 10 founding members have brought 22 treatments to market and currently have more than 160 rare disease programs in the works.
-
CytRx Comments on Quarterly Results and Year-to-Date Progress
5/13/2021
CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on its results for the first quarter
-
The “Rare Disease Company Coalition” Launches to Share the Unique Challenges and Promise of Rare Disease Therapy Development to Support Continued Progress and Patient Access
5/13/2021
The Rare Disease Company Coalition , a unified voice of life science companies today announced their organizational launch.